NCT00985426View on ClinicalTrials.gov

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

521

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Chronic Kidney Disease
Interventions
BIOLOGICAL

HEPLISAV-B

Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24

BIOLOGICAL

Engerix-B

Intramuscular (IM) injections at Weeks 0, 4, 8, and 24

OTHER

Placebo

Placebo(saline) intramuscular (IM) injection at Week 8

Trial Locations (1)

23507

Clinical Research Associates of Tidewater, Norfolk

Sponsors
All Listed Sponsors
lead

Dynavax Technologies Corporation

INDUSTRY

NCT00985426 - Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients | Biotech Hunter | Biotech Hunter